Find the latest episode of "The Uncertain Hour" here. Listen

Superbugs create super opportunity

Helen Palmer Jun 7, 2007

TEXT OF STORY

MARK AUSTIN THOMAS: Sometimes a hospital isn’t the best place to get well. It’s becoming increasingly full of dangerous bugs resistant to antibiotics. About 5 out of every 100 patients catches an infection there. But, Helen Palmer reports from the Health Desk at WGBH, those statistics represent an opportunity for the pharmaceutical industry.

Helen Palmer: In recent years, terms like Methicillin-resistant Staphylococcusaureus — or MRSA— have begun to trip off our tongues as these dangerous bacteria have become a widespread problem in hospitals. New analysis says the costs are huge.

Mansi Shah: There’s probably about $1.5 billion spent on hospital acquired infections.

Mansi Shah is an analyst with research company Datamonitor. She says the drug industry’s risen to the challenge with effective new but pricey antibacterials. Pfizer’s Zyvox, for example, costs about $150 a day.

Shah: There’s lots of companies who’ve targeted that particular market and there’s lots of drugs in the pipeline targeted towards the MRSA market.

But Shah says choices are very limited for other resistant bacteria, including bugs that cause hospital-acquired pneumonia. Only one company, Johnson & Johnson, has drugs in the pipeline to tackle that. It filed for FDA approval of one just yesterday.

In Boston, I’m Helen Palmer for Marketplace.

TEXT OF STORY

MARK AUSTIN THOMAS: Sometimes a hospital isn’t the best place to get well. It’s becoming increasingly full of dangerous bugs resistant to antibiotics. About 5 out of every 100 patients catches an infection there. But, Helen Palmer reports from the Health Desk at WGBH, those statistics represent an opportunity for the pharmaceutical industry.

Helen Palmer: In recent years, terms like Methicillin-resistant Staphylococcusaureus — or MRSA— have begun to trip off our tongues as these dangerous bacteria have become a widespread problem in hospitals. New analysis says the costs are huge.

Mansi Shah: There’s probably about $1.5 billion spent on hospital acquired infections.

Mansi Shah is an analyst with research company Datamonitor. She says the drug industry’s risen to the challenge with effective new but pricey antibacterials. Pfizer’s Zyvox, for example, costs about $150 a day.

Shah: There’s lots of companies who’ve targeted that particular market and there’s lots of drugs in the pipeline targeted towards the MRSA market.

But Shah says choices are very limited for other resistant bacteria, including bugs that cause hospital-acquired pneumonia. Only one company, Johnson & Johnson, has drugs in the pipeline to tackle that. It filed for FDA approval of one just yesterday.

In Boston, I’m Helen Palmer for Marketplace.

Marketplace is on a mission.

We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.

Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?

Your donation is critical to the future of public service journalism. Support our work today – for as little as $5 – and help us keep making people smarter.